Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Bishop who wrote (93422)	10/11/2001 10:07:18 AM
From: Kevin Clarke	Respond to of 150070

BioShield Answers U.S. and Other International Governmental Inquiries Regarding the Use of BioShield's Antimicrobial Molecule Agent Against Anthrax BioShield Researchers Continue Studying (Developing) New Procedures To Eliminate the Cross-Contamination of Harmful Bacteria ATLANTA, Oct. 11 /PRNewswire/ -- BioShield Technologies, Inc. (OTC Bulletin Board: BSTI - news) announced today that over the last 72 hours the company has received inquiries from military departments and contractors -- Camber; Objective Individual Combat Weapon (OTCW); Objective Crew Served Weapon (OCSW); Sam Whitfield, Commander of U.S. Army Infantry Center ATSH-OTY; Hospitals; Laboratories; and the International corporation of Airport security in Germany and Ireland regarding the use of BioShield's antimicrobial agent against Anthrax. BioShield's microbiologists believe BioShield's products are effective against the Bacillus Anthracis, the bacteria that causes Anthrax. BioShield's in-house laboratories have tested BioShield products against a wide variety of Gram-positive and Gram-negative bacteria from the same family of Bacillus Anthracis, such as Bacillus Subtilis, with a 100% success rate of eliminating the bacteria. An interview, seen on CNN Wednesday evening, with Dr. Larry Bush, Infectious Disease Specialist, who diagnosed the Florida patients with having Anthrax, reflected on the Bacillus Anthracis bacteria. BioShield has been in contact with the CDC in Atlanta, GA; Los Alamos National Laboratory in Los Alamos, New Mexico; and a military research organization in an effort to secure a suitable testing facility and to discuss the value, if any, of using BioShield's technology as a protective agent against Bacillus Anthracis. Outside testing is necessary because of the high risk and level of transmission of spores. Specialists in the field of Anthrax are being sought out, as stated, to determine if the unique attributes of BioShield's chemical molecule agent can contribute to stopping the dissemination of Anthrax and reducing the potential risk of Anthrax. BioShield's patented chemical technology is the world's first residual antimicrobial molecule approved by the E.P.A. for multiple consumer/institutional uses. The company's active molecule has the unique ability to bind itself to hundreds of types of surfaces thus creating essentially a new surface that is protected and inhibits the growth of bacteria for extended periods of time and should help stop cross- contamination. BioShield's technology as stated above is currently approved by the Environmental Protection Agency (E.P.A.) for fogging in institutional and industrial facilities and homeowner dwellings. It can be simply sprayed on surfaces or washed into clothing. The technology's staying power is longest, up to 3 years, when blended in with fibers. Moreover, BioShield's antimicrobial does not leach off into the environment, making it much safer to use than traditional chemicals if widely dispersed. Safe Harbor/Forward-Looking Statements Statements in this news release that are not historical are forward- looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of BioShield; the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. BioShield does not undertake to revise or update any forward-looking statements to reflect events or circumstances that may arise after the date hereof. BioShield is a trademark of BioShield Technologies, Inc.